Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLRB Cellectar Biosciences	$0.41 -5.4%	$0.29	$0.22 ▼ $3.34	$19.04M	0.52	3.99 million shs	2.64 million shs
HOTH Hoth Therapeutics	$1.30 -8.5%	$0.93	$0.58 ▼ $3.80	$17.17M	0.55	3.68 million shs	715,000 shs
PMN ProMIS Neurosciences	$0.52 -0.1%	$0.55	$0.47 ▼ $2.37	$16.98M	-0.08	78,750 shs	19,524 shs
TZAC Tenzing Acquisition	$0.73 -6.9%	$9.02	$8.33 ▼ $15.10	$3.72M	0.01	46,767 shs	773,164 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLRB Cellectar Biosciences	-5.45%	+14.52%	+71.67%	+30.93%	-87.59%
HOTH Hoth Therapeutics	-8.45%	0.00%	+49.43%	+17.12%	+31.54%
PMN ProMIS Neurosciences	-0.10%	+8.68%	+2.87%	-32.18%	-69.08%
TZAC Tenzing Acquisition	-1.63%	-2.50%	-6.51%	-29.73%	-47.65%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLRB Cellectar Biosciences	2.6587 of 5 stars	3.2	5.0	0.0	0.0	3.3	0.0	0.6
HOTH Hoth Therapeutics	3.1942 of 5 stars	3.6	5.0	0.0	0.0	1.7	0.8	1.3
PMN ProMIS Neurosciences	2.3232 of 5 stars	3.5	2.0	0.0	0.0	3.3	0.8	0.6
TZAC Tenzing Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLRB Cellectar Biosciences	2.33	Hold	$12.50	2,925.17% Upside
HOTH Hoth Therapeutics	3.25	Buy	$4.00	207.69% Upside
PMN ProMIS Neurosciences	3.00	Buy	$4.50	766.22% Upside
TZAC Tenzing Acquisition	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TZAC, CLRB, PMN, and HOTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
5/14/2025	CLRB Cellectar Biosciences	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/12/2025	PMN ProMIS Neurosciences	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$3.00
4/15/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/1/2025	PMN ProMIS Neurosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/31/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	($0.96) per share	N/A
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	$2.03 per share	N/A
PMN ProMIS Neurosciences	N/A	N/A	N/A	N/A	$0.20 per share	N/A
TZAC Tenzing Acquisition	N/A	N/A	$0.01 per share	143.10	$0.98 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLRB Cellectar Biosciences	-$42.77M	-$0.73	N/A	N/A	N/A	N/A	N/A	-191.22%	8/11/2025 (Estimated)
HOTH Hoth Therapeutics	-$7.84M	-$1.14	N/A	N/A	N/A	N/A	-89.68%	-82.61%	8/8/2025 (Estimated)
PMN ProMIS Neurosciences	-$13.21M	-$0.05	N/A	N/A	N/A	N/A	-636.20%	-130.32%	8/6/2025 (Estimated)
TZAC Tenzing Acquisition	$620K	N/A	0.00	∞	N/A	N/A	-13.32%	-1.36%	N/A

Latest TZAC, CLRB, PMN, and HOTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	CLRB Cellectar Biosciences	-$0.17	-$0.13	+$0.04	-$0.14	N/A	N/A
5/12/2025	Q1 2025	HOTH Hoth Therapeutics	-$0.34	-$0.27	+$0.07	-$0.27	N/A	N/A
5/12/2025	Q1 2025	PMN ProMIS Neurosciences	-$0.14	-$0.21	-$0.07	-$0.21	N/A	N/A
3/31/2025	Q4 2024	PMN ProMIS Neurosciences	-$0.14	-$0.02	+$0.12	-$0.02	N/A	N/A
3/27/2025	Q4 2024	HOTH Hoth Therapeutics	-$0.39	-$0.32	+$0.07	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	N/A
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	N/A
PMN ProMIS Neurosciences	N/A	N/A	N/A	N/A	N/A
TZAC Tenzing Acquisition	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLRB Cellectar Biosciences	N/A	1.77	1.77
HOTH Hoth Therapeutics	N/A	10.17	10.17
PMN ProMIS Neurosciences	N/A	9.30	9.30
TZAC Tenzing Acquisition	0.28	0.05	0.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLRB Cellectar Biosciences	16.41%
HOTH Hoth Therapeutics	7.08%
PMN ProMIS Neurosciences	50.13%
TZAC Tenzing Acquisition	60.89%

Insider Ownership

Company	Insider Ownership
CLRB Cellectar Biosciences	5.04%
HOTH Hoth Therapeutics	10.56%
PMN ProMIS Neurosciences	6.11%
TZAC Tenzing Acquisition	37.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLRB Cellectar Biosciences	10	46.08 million	44.38 million	Optionable
HOTH Hoth Therapeutics	4	13.21 million	6.18 million	Not Optionable
PMN ProMIS Neurosciences	5	32.69 million	31.25 million	Not Optionable
TZAC Tenzing Acquisition	N/A	5.12 million	N/A	Not Optionable

TZAC, CLRB, PMN, and HOTH Headlines

Recent News About These Companies

From the Archives, 1953: Hillary and Norgay reach the top of the world

June 8, 2023 | smh.com.au

NYC Street in Queens to be Co-named After Tenzing Norgay Sherpa

April 21, 2023 | patch.com

Tenzing Acquisition Corp. News

October 15, 2022 | thestreet.com

A 'Gift to the Queen': The First Ever Successful Summit of Mount Everest

September 22, 2022 | thewire.in

Tenzing Norgay Trainor Biography & Movies

September 14, 2022 | tribute.ca

Reviva Pharmaceuticals Holdings, Inc. Common Stock (RVPH)

August 12, 2021 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TZAC, CLRB, PMN, and HOTH Company Descriptions

Cellectar Biosciences NASDAQ:CLRB

$0.41 -0.02 (-5.45%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$0.35 -0.06 (-14.33%)

As of 06/13/2025 07:59 PM Eastern

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Hoth Therapeutics NASDAQ:HOTH

$1.30 -0.12 (-8.45%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.32 +0.02 (+1.92%)

As of 06/13/2025 07:58 PM Eastern

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

ProMIS Neurosciences NASDAQ:PMN

$0.52 0.00 (-0.19%)

As of 06/13/2025 03:54 PM Eastern

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Tenzing Acquisition NASDAQ:TZAC

Tenzing Acquisition Corp. does not have significant operations. It intends to acquire, engage in a share exchange, share reconstruction and amalgamation with, purchase all or substantially all of the assets of, enter into contractual arrangements with, or engage in any other similar business combination with one or more businesses or entities primarily operates in India. The company was founded in 2018 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time